schizophrenia. schizophrenia
Conditions
Interventions
Intervention 1: Tablet Risperidone (6 mg/day) combined with placebo as control group for 8 weeks. Intervention 2: Tablet Risperidone (6 mg/day) combined with 2 gr/day L carnosine as intervention group
Placebo
Treatment - Drugs
Tablet Risperidone (6 mg/day) combined with 2 gr/day L carnosine as intervention group for 8 weeks
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria:1-Diagnosis of Schizophrenia based on DSM-5 criteria; 2- Age between 18-60; 3-Chronic Schizophrenia- duration of the disorder more than 2 years; 4-Minimum score of 20 in negative sub score. 5-being stable on risperidone for the last 2 months Exclusion criteria:1-Any serious medical or neurological problem; 2- IQ less than 70; 3- Substance dependence during the last 6 months(except for nicotine and caffeine); 4- Score on HDRS less than 14 5-receiving ECT during the last 3 months ; 6-Acute or chronic systemic diseases; 7- History of neurosurgery; 8- History of head trauma.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-8 after beginig of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactProf. Shahin Akhondzadeh
Tehran University of Medical Sciences
Outcome results
None listed